Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBOC-201 versus normal saline for prehospital haemorrhagic shock in major trauma
ACTRN12615000522516Phase 2Not yet recruiting
- Sponsor
- Alfred Health
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hemoglobin glutamer-250 and Normal Saline-Benha University in hemorrhagic shock and Major trauma (2 arms), sponsored by Alfred Health. Primary endpoint: Mortality. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
hemoglobin glutamer-250Normal Saline-Benha University
03
Conditions
hemorrhagic shockMajor trauma
Beyond the preview
Go deeper on ACTRN12615000522516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000522516.